PPA
CERE

Parametric Portfolio Associates’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Parametric Portfolio Associates’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$808K Sell
23,090
-40,199
-64% -$1.17M ﹤0.01% 2875
2021
Q4 		$2.05M Buy
63,289
+7,650
+14% +$270K ﹤0.01% 2422
2021
Q3 		$1.64M Buy
55,639
+21,446
+63% +$602K ﹤0.01% 2544
2021
Q2 		$876K Buy
+34,193
New +$489K ﹤0.01% 2829

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $4.82B AUM 35.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Parametric Portfolio Associates's CERE Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) stake by 64% in Q1 2022, selling an estimated $1.17M and leaving 23,090 shares worth $808K. The position accounts for ﹤0.01% of the portfolio, ranked #2875.

Parametric Portfolio Associates first reported a position in CERE in Q2 2021 and has held it in 4 quarters since. The position peaked at $2.05M in Q4 2021. 107 funds tracked by Wall St. Rank hold CERE as of Q1 2022.

  • Parametric Portfolio Associates held 23,090 shares of Cerevel Therapeutics Holdings, Inc. Common Stock worth $808K as of Q1 2022.
  • Parametric Portfolio Associates sold 40,199 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q1 2022, an estimated $1.17M.
  • Cerevel Therapeutics Holdings, Inc. Common Stock made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2875 holding.
  • Parametric Portfolio Associates first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2021 and has held it in 4 quarters since.
  • Parametric Portfolio Associates's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $2.05M in Q4 2021.
  • 107 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.